Futura Medical plc

AIM:FUM Stock Report

Market Cap: UK£100.6m

Futura Medical Valuation

Is FUM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FUM (£0.33) is trading below our estimate of fair value (£1.8)

Significantly Below Fair Value: FUM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FUM?

Key metric: As FUM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FUM. This is calculated by dividing FUM's market cap by their current revenue.
What is FUM's PS Ratio?
PS Ratio11.9x
SalesUK£8.40m
Market CapUK£100.62m

Price to Sales Ratio vs Peers

How does FUM's PS Ratio compare to its peers?

The above table shows the PS ratio for FUM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.6x
STX Shield Therapeutics
1.4x46.9%UK£23.1m
REDX Redx Pharma
13.9x-37.6%UK£58.3m
ANCR Animalcare Group
2x3.8%UK£148.5m
APH Alliance Pharma
1.3x5.2%UK£240.6m
FUM Futura Medical
11.9x34.0%UK£100.3m

Price-To-Sales vs Peers: FUM is expensive based on its Price-To-Sales Ratio (11.9x) compared to the peer average (4.6x).

Price to Sales Ratio vs Industry

How does FUM's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x5.9%US$56.33m
No more companies available in this PS range
FUM 11.9xIndustry Avg. 3.1xNo. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FUM is expensive based on its Price-To-Sales Ratio (11.9x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is FUM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FUM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.9x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: FUM is expensive based on its Price-To-Sales Ratio (11.9x) compared to the estimated Fair Price-To-Sales Ratio (5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FUM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.33
UK£1.34
+302.9%
3.4%UK£1.40UK£1.30n/a3
Nov ’25UK£0.37
UK£1.34
+262.5%
3.4%UK£1.40UK£1.30n/a3
Oct ’25UK£0.34
UK£1.34
+293.1%
3.4%UK£1.40UK£1.30n/a3
Sep ’25UK£0.34
UK£1.26
+277.1%
2.7%UK£1.31UK£1.23n/a3
Aug ’25UK£0.36
UK£1.26
+250.9%
2.7%UK£1.31UK£1.23n/a3
Jul ’25UK£0.38
UK£1.26
+236.7%
2.7%UK£1.31UK£1.23n/a3
Jun ’25UK£0.37
UK£1.26
+238.2%
2.7%UK£1.31UK£1.23n/a3
May ’25UK£0.33
UK£1.26
+284.0%
2.7%UK£1.31UK£1.23n/a3
Apr ’25UK£0.41
UK£1.26
+211.1%
4.0%UK£1.31UK£1.21n/a2
Mar ’25UK£0.42
UK£1.26
+201.4%
4.0%UK£1.31UK£1.21n/a2
Feb ’25UK£0.29
UK£1.26
+334.5%
4.0%UK£1.31UK£1.21n/a2
Jan ’25UK£0.26
UK£1.26
+394.1%
4.0%UK£1.31UK£1.21n/a2
Dec ’24UK£0.31
UK£1.26
+306.5%
4.0%UK£1.31UK£1.21n/a2
Nov ’24UK£0.29
UK£1.26
+341.3%
4.0%UK£1.31UK£1.21UK£0.372
Oct ’24UK£0.42
UK£1.26
+196.5%
4.0%UK£1.31UK£1.21UK£0.342
Sep ’24UK£0.52
UK£1.23
+136.5%
23.6%UK£1.52UK£0.94UK£0.342
Aug ’24UK£0.55
UK£1.23
+124.5%
23.6%UK£1.52UK£0.94UK£0.362
Jul ’24UK£0.60
UK£1.18
+96.7%
20.3%UK£1.42UK£0.94UK£0.382

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$744.64

7D

-6.6%

1Y

-7.2%

Formycon

€821.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.50

7D

-1.0%

1Y

-24.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€61.75

7D

-5.2%

1Y

16.1%